Why This FDA Update Is Crucial for Fulcrum Therapeutics and COVID-19
The FDA has notified Fulcrum Therapeutics that it is allowed to proceed with initiating its Phase 3 trial of losmapimod in higher risk hospitalized adults with COVID-19.
All Work
Chris Lange
Is the Nintendo Switch About to Be Overrun by Competition?
Nintendo always has been one of the major players in the video game industry, but this year it may be outmatched as the holiday season is on the way.
GW Pharma Makes Big Regulatory Step for Cannabidiol in UK
GW Pharmaceuticals took a big step forward for the development of its cannabidiol product in the United Kingdom.
Existing Home Sales Continue to Drop, but Realtors Are Optimistic
Existing home sales plunged in May, according to the National Association of Realtors. But does this represent a bottom in the market?
Why This Capital Injection Is Huge for Inovio
Inovio Pharmaceuticals has announced that it received $71 million in funding from the U.S. Department of Defense to support the production of its delivery device for the COVID-19 vaccine.
How Salesforce and Siemens Aim to Fight COVID-19
Salesforce.com is looking to get people back to work in the age of COVID with a recently announced a strategic partnership with Siemens.
Why the Sanofi and Translate Bio Vaccine Pact Is Win-Win
Sanofi and Translate Bio are making waves in the fight against the novel coronavirus as the two have agreed to expand their existing 2018 collaboration and license agreement
Gold Bugs Have to Be Happy With This
Gold is making a great case for itself this year, and gold bugs have to be happy about that. The strategists at JPMorgan have a bullish view on gold.
Should Investors Trust Bill Ackman With This Blank Check IPO?
Pershing Square Tontine Holdings has filed with the SEC regarding its initial public offering.
Sintx Tech Gains Full Coronavirus Stock Status With New Study
Sintx Technologies shares nearly tripled after the company announced a big win against the coronavirus in a controlled laboratory study.
Why This FDA Approval Puts Evoke Pharma in the Money
Evoke Pharma says the FDA has approved its New Drug Application for Gimoti nasal spray for symptom relief in adults with acute and recurrent diabetic gastroparesis.
Tyson Foods Is Playing a Game of COVID Chicken With China
Tyson Foods took a hit on Monday after it came to light that China’s customs agency has suspended poultry imports from one of the company’s facilities in Arkansas. The suspension is COVID-19 related.
What Virgin Galactic’s NASA Deal Means for Space Flight Privatization
Virgin Galactic has signed a Space Act Agreement with NASA’s Johnson Space Center to encourage commercial participation in orbital human spaceflight to the International Space Station.
BlackBerry, KB Home, Nike and More Earnings Coming This Week
Here, 24/7 Wall St. offers a preview of what to expect from BlackBerry, Nike and some of the other key companies on deck to report quarterly results this week.
Penn National Gaming Moves All In on Reopening Efforts
An update on its gaming and racing properties helped boost Penn National Gaming shares to close out the week.
DraftKings Ups the Ante in Secondary Offering
DraftKings is moving forward with its secondary offering, but it will be upsized from the previous announcement.
2020 IPO Next-Gen Cancer Screening AnPac Sees Growth in US and China
The announcement that AnPac Bio-Medical Science has entered into a three-year strategic cancer screening collaboration contract with Beijing Yuan Jian Health Management in China lit a fire under the shares Friday morning.
Are Smith & Wesson Earnings Really Not Enough for Investors?
Strong consumer demand for firearms helped Smith & Wesson deliver growth and market share gains in its firearms business in fiscal 2020.
Why Spotify’s DC Deal Is All Around Super
Spotify Technology is putting on its cape and saving the day for investors with its newest superhero deal with DC Comics.
How Sarepta and Selecta Bio Are Taking the Fight to DMD
Selecta Biosciences and Sarepta Therapeutics have announced that they had entered into a research license and option agreement.